Award Number: W81XWH-11-1-0310

TITLE: Validating Diagnostic and Screening Procedures for Pre-Motor Parkinson’s Disease

PRINCIPAL INVESTIGATOR: Dr. J William Langston

CONTRACTING ORGANIZATION: Parkinson’s Institute
Sunnyvale, CA 94085-2934

REPORT DATE: April 2014

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
1. REPORT DATE  
April 2014

2. REPORT TYPE  
Annual Report

3. DATES COVERED  
1 April 2011 – 31 March 2014

4. TITLE AND SUBTITLE  
Validating Diagnostic and Screening Procedures for Pre-motor Parkinson’s Disease

5a. CONTRACT NUMBER  
W81XWH-11-1-0310

5b. GRANT NUMBER  
W81XWH-11-1-0310

5c. PROGRAM ELEMENT NUMBER  
R

5d. PROJECT NUMBER  
E

5e. TASK NUMBER  

5f. WORK UNIT NUMBER  

6. AUTHOR(S)  
Dr. J William Langston  
Dr. Samuel M. Goldman

E-Mail: jwlangston@thepi.org and sgoldman@thepi.org

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  
675 Almanor Avenue  
Sunnyvale, CA 94085-2934

8. PERFORMING ORGANIZATION REPORT NUMBER  

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)  
USAMRMC

11. SPONSOR/MONITOR'S REPORT NUMBER(S)  

12. DISTRIBUTION / AVAILABILITY STATEMENT  
Approved for Public Release; Distribution Unlimited

14. ABSTRACT  
The goal of this 24-month proposal is to establish the critical infrastructure for the initiation of a five year prospective follow-up study to identify those at risk for developing PD or a related Lewy body disorder in three study populations. The ultimate goal of this work is to develop low-cost non-invasive screening methods to detect pre-motor Parkinson’s disease (PD) that can be implemented population-wide. Our hypothesis is that cardiac autonomic dysfunction assessed as heart rate variability (HRV) using a standard EKG, in combination with hyposmia and other simple screening tests, will be highly predictive of abnormalities in DAT imaging and ultimately predict the emergence of full-blown PD or a related Lewy body disorder.

15. SUBJECT TERMS  
Pre-motor; Parkinson's Disease; Lewy Body Disease; REM Behavior Disorder (RBD); Cardiac dysautonomia; Electrocardiogram; Heart Rate Variability (HRV); Diagnostic Screening

16. SECURITY CLASSIFICATION OF:  

<table>
<thead>
<tr>
<th>a. REPORT</th>
<th>b. ABSTRACT</th>
<th>c. THIS PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>U</td>
<td>U</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17. LIMITATION OF ABSTRACT</th>
<th>18. NUMBER OF PAGES</th>
<th>19a. NAME OF RESPONSIBLE PERSON</th>
</tr>
</thead>
<tbody>
<tr>
<td>UU</td>
<td>7</td>
<td>USAMRMC</td>
</tr>
</tbody>
</table>

19b. TELEPHONE NUMBER (include area code)  

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cover</td>
<td>1</td>
</tr>
<tr>
<td>SF 298</td>
<td>2</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>3</td>
</tr>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>5</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>7</td>
</tr>
<tr>
<td>Conclusions</td>
<td>7</td>
</tr>
<tr>
<td>References</td>
<td>7</td>
</tr>
<tr>
<td>Appendices</td>
<td>7</td>
</tr>
</tbody>
</table>
INTRODUCTION

This work addresses the next frontier in Parkinson’s disease (PD) research: developing new tools to diagnose PD in its earliest stages, well before motor symptoms manifest. Currently, PD is diagnosed only when classic motor features present, when 60-80% of striatal dopamine is already depleted. Clinical trials with neuroprotective agents are much more likely to succeed if carried out before the major portion of the damage has already been incurred. However, these transformative goals will be clinically useful for screening the general population only if non-invasive tools can be easily administered in the primary care physician’s office. Our hypothesis is that cardiac autonomic dysfunction assessed as heart rate variability (HRV) using a standard EKG, in combination with hyposmia and other simple screening tests, will be highly predictive of abnormalities in dopamine transporter (DAT) imaging and ultimately predict the emergence of full-blown PD or a related Lewy body disorder. The ability to identify individuals with pre-motor PD could have enormous public health consequences, particularly once an effective disease-modifying therapy is identified. Our goal is to develop a battery of tools to identify pre-motor PD that can be administered with relative ease and low cost, such that it can be incorporated into a routine annual physical examination, beginning when individuals reach an age where they are at increased risk for PD.

BODY

This 24-month proposal will establish the critical infrastructure for the initiation of a five year prospective follow-up study to identify those at risk for developing PD or a related Lewy body disorder in three study populations. The current proposal has four objectives: 1) to develop the required internal and collaborative infrastructure to establish a large cohort with idiopathic REM behavior disorder and test a comprehensive clinical assessment protocol for pre-motor PD, 2) to establish a protocol for collecting digital EKGs from collaborating studies, 3) to initiate data collection in each study population, and 4) to conduct preliminary analyses of EKG data for HRV. On January 28, 2013 we requested a 12-month extension of the Period of Performance to support completion of the above award. The extension was approved on January 31, 2013 (revised period of performance April 30, 2014, research ending March 31, 2014). On March 14, 2014 we requested a second 12-month extension of the Period of Performance to support the completion of the above award. Regulatory approval of the project was extremely complicated, requiring review and coordination between the regulatory agency of the Parkinson's Institute and the USAMRMC HRPO. The approval delays prevented initiation of the actual human contact work and receipt of data from collaborating institutions for a prolonged time. After HRPO approval was received, enrollment of eligible subjects has proceeded more slowly than anticipated. However, we have made major progress toward completion of the statement of work and have developed effective case recruitment methods. Substantial progress has been made utilizing these new recruitment methods. The newly approved extension is effective April 1, 2014 (revised period of performance is April 30, 2015, research ending March 31, 2015). With approval of the extension, we expect to accomplish the funded work as originally described. There have been no modifications to the statement of work as originally described.
KEY RESEARCH ACCOMPLISHMENTS AS OF 31 MARCH, 2014

1) Assemble an iRBD Cohort:
   a) Identify eligible iRBD patients and controls
      i) Establish collaborative relationships with all San Francisco Bay Area sleep
         medicine clinics
      ii) Develop physician outreach methods and materials
      iii) Develop community outreach methods and materials
      iv) Develop RBD screening methods to identify likely cases

   Progress to date:
   • Cohort recruitment is ongoing
   • We have, and continue to actively establish collaborative relationships with
     San Francisco Bay Area sleep medicine clinics
   • Physician outreach materials have been developed. Materials continue to be
     distributed to sleep clinics and neurologists in the region
   • Subject recruitment materials have been developed and IRB approved, and
     continue to be distributed
   • Direct outreach recruitment methods are being implemented

   Milestones Remaining:
   • Complete iRBD case and control recruitment (estimated completion: December 31, 2014)

b) Standardize application of diagnostic criteria for iRBD.
   i) Develop methods for rescoring polysomnographic (PSG) data and applying
      diagnostic criteria

   Progress to date: Completed. As specified in the study protocol, some subjects with
   suspected iRBD have undergone de novo PSGs. De novo PSGs will continue to be
   conducted as needed.

c) Develop a secure database to track subject recruitment and enrollment efforts
   Progress to date: Completed. A secure relational database has been developed and
   continues to be populated.

d) Prepare and submit study documents for institutional review board (IRB) approval
   Progress to date: Completed. Continuing review documents were submitted to El
   Camino Hospital on October 29, 2013. These were reviewed and approved by the El
   Camino Hospital IRB at their meeting on November 15, 2013 and we received the
   new approval letter from the El Camino Hospital IRB on November 19, 2013. The
   study expiration date is November 15, 2014. There were no modifications to the
   protocol or consent forms since these documents were last submitted to HRPO. On
   January 9, 2014 we sent the continuing review report, new approval letter from the El
   Camino IRB, current protocol and current consent forms to Ms. Kirdnual at
   USAMRC ORP HRPO.
e) Develop the clinical assessment protocol
   i) Develop standardized clinical data collection protocols
   ii) Create scannable data collection forms for all clinical instruments
   iii) Develop blood processing and storage protocols
   iv) Pilot test clinical data-collection methods

   Progress to date: Completed

f) Develop an operations manual

   Progress to date: Completed

g) Develop clinical databases, a data dictionary and quality assurance procedures

   Progress to date: Completed

2) Establish digital EKG collection in the APDC cohort: We will work with APDC staff to establish a protocol for collection of digital EKGs and transfer of data to the Parkinson’s Institute

   Progress to date: Completed

3) Establish a study steering committee:
   Convene a steering committee meeting at the Parkinson’s Institute

   Progress to date: Estimated completion: December 31, 2014

4) Implement data collection in each study population:
   a) iRBD cohort: Begin enrolling and characterizing iRBD subjects
   b) PARS cohort & APDC cohorts: Baseline digital EKG data will be collected at regular follow-up assessments and transferred to the Parkinson’s Institute at regular intervals using secure protocols

   Progress to date: USAMRC ORP HRPO approval has been received to establish an iRBD cohort, and to receive de-identified data from PARS and APDC.
   - iRBD cohort enrollment has commenced. Clinical evaluations and DaTSCAN imaging are ongoing. Estimated completion: December 31, 2014
   - PARS EKG data transfers have commenced and are ongoing. Estimated completion: September 30, 2014
   - APDC EKG data transfers have commenced and are ongoing. Estimated completion: September 30, 2014

5) Data analysis:
   a) Digital EKG data will be analyzed for 15 HRV parameters
   b) Descriptive analyses for each cohort, and preliminary explorations of associations between HRV, hyposmia and other putative pre-motor features will be performed as possible, based on subject accrual

   Progress to date:
   - HRV analyses of EKGs obtained from PARS are ongoing. Estimated completion: December 31, 2014
   - HRV analyses for EKGs obtained from APDC are ongoing. Estimated completion: December 31, 2014
- HRV analyses for EKGs obtained from the iRBD cohort are ongoing. Estimated completion: January 31, 2014
- Descriptive analyses and preliminary explorations of associations are pending completion of data collection. Estimated completion: March 31, 2015

REPORTABLE OUTCOMES

None at this time.

CONCLUSIONS

Substantial progress has been made. Important next steps for the project include the following:

- continue to ascertain, enroll and clinically evaluate iRBD cohort members
- ongoing receipt and analysis of de-identified data from PARS
- ongoing receipt and analysis of de-identified data from APDC
- convene a study steering committee meeting
- ongoing data entry and quality assurance processes
- develop and implement an analytic plan

REFERENCES

None

APPENDICES

None